Acute myeloid leukemia

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

Retrieved on: 
Tuesday, January 9, 2024
Pancreatic cancer, Research, Biology, Prostate cancer, Cancer, Cytokine release syndrome, CRS, AML, Population Reference Bureau, Audit committee, AMGN, NK, Neoplasm, ADC, Acute myeloid leukemia, Paracetamol, PMR, NKG2D, NSCLC, Disease, Safety, Conditional sentence, Brain, Lung cancer, Breast, PALM, Cytarabine, Senior, Prevalence, Genetics, Nonsteroidal anti-inflammatory drug, Drug discovery, Graft-versus-host disease, Ruxolitinib, TSX, Therapy, Kidney cancer, Ageing, Patient, Stomach, Complete Response Letter, Fentanyl, Breast cancer, Novartis, Society, Eli Lilly, News, Food, Cancer pain, Johnson & Johnson, Morphine, FDA, Ovarian cancer, New Drug Application, ASH, ONC, Pharmaceutical industry

Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.

Key Points: 
  • Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades.
  • The entire medical research fraternity has prioritized cancer research in order to find new ways of treatment and analysis.
  • According to Nova one advisor, the global Oncology Cancer Drugs market was valued at USD 147.2 billion in 2021 and it is expected to hit around USD 289.2 billion by 2030 with a CAGR of 8.4% during the forecast period 2022 to 2030.
  • The article continued: “Drugs such as morphine, fentanyl, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and others are used extensively in treating cancer pain in patients with lung cancer, bone cancer, and other types of cancer.

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

Retrieved on: 
Tuesday, January 9, 2024
Venetoclax, Patient, CRC, MRD, EFS, MD, OS, Acute myeloid leukemia, SLS, COVID, PD, Standard of care, Azacitidine, Food, COVID 19, Disease, Safety, Doctor of Science, Sepsis, Fast Track, FDA, AML, Treatment, CDK9, Pharmaceutical industry

NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to SLS009 (formerly GFH009), its novel and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory (r/r) acute myeloid leukemia (AML). The Fast Track Designation is intended to facilitate the development and review of drugs to treat serious conditions and fill an unmet medical need.

Key Points: 
  • The Fast Track Designation is intended to facilitate the development and review of drugs to treat serious conditions and fill an unmet medical need.
  • Importantly, as of the last follow-up, eight of the nine patients enrolled in the 45 mg cohort were alive.
  • The first patient enrolled in the study achieved a complete response (CR) and continues on study in the seventh month with full peripheral blood recovery.
  • Eight patients (89%) remain alive (one patient succumbed to sepsis having previously contracted COVID 19) and six continue treatment.

City of Hope Research Reveals an Immune Cell That Can Attack Cancer

Retrieved on: 
Wednesday, January 10, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NK, Neoplasm, Patient, Leukemia, Glioblastoma, Acute myeloid leukemia, ILC2, City, Multimedia, Hematology, Mouse, Haematopoietic system, Freezing, Cancer, Allergy, Weill Cornell Medicine, Michael Kors, Lung cancer, Immunology, COVID-19, Virus, Bone marrow, Organization, Inflammatory bowel disease, AML, Immunity, Bangladesh Technical Education Board, Pancreatic cancer, Vaccine

According to preclinical research published online today in Cell , one of the world’s premier scientific journals, researchers with City of Hope®, one of the largest cancer treatment and research organizations in the United States, have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer.

Key Points: 
  • According to preclinical research published online today in Cell , one of the world’s premier scientific journals, researchers with City of Hope®, one of the largest cancer treatment and research organizations in the United States, have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer.
  • View the full release here: https://www.businesswire.com/news/home/20240109475331/en/
    City of Hope researchers discovered that ILC2s, pictured here, can attack cancer cells.
  • However in the highly translational labs at City of Hope, researchers prioritized the examination of human cells and found that human ILC2s do not work the same as mouse ILC2s.
  • In fact, Yu is founding director of the Natural Killer Cell Biology Research Program at City of Hope, a national leader in the field.

AHEAD Medicine Corporation Reveals Cross-Test AML Diagnostic Technique at ASH 2023

Retrieved on: 
Thursday, January 11, 2024
SAN, Beckman Coulter, Classification, ASH, Poster, Acute myeloid leukemia, Conference, Research, Flow cytometry, Society

SAN JOSE, Calif., Jan. 11, 2024 /PRNewswire/ -- AI HealthTech startup AHEAD Medicine Corporation is delighted to announce its poster presentation at the esteemed American Society of Hematology (ASH) 2023 Conference.

Key Points: 
  • SAN JOSE, Calif., Jan. 11, 2024 /PRNewswire/ -- AI HealthTech startup AHEAD Medicine Corporation is delighted to announce its poster presentation at the esteemed American Society of Hematology (ASH) 2023 Conference.
  • The study presented at ASH 2023 focused on the integration of diagnostic data measured using both BD Biosciences and Beckman Coulter panels.
  • AHEAD Medicine's dedication to enhancing healthcare access through innovative data analysis in healthcare is reflective of its ongoing mission to devise solutions that navigate the intricacies of contemporary medicine.
  • For further details about AHEAD Medicine and to view the poster at ASH 2023, please visit https://www.aheadmedicine.com/publications/2023ash

GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia

Retrieved on: 
Thursday, January 11, 2024
Oncogene, FTD, MYC, Patient, Therapy, Accelerated approval (FDA), Acute myeloid leukemia, Venetoclax, Food and Drug Administration, ODD, Azacitidine, Food, MCL1, NDA, Safety, Priority review, FDA, BLA, Marketing, AML, Bone marrow, PTCL, CDK9, Pharmaceutical industry

GFH009 (highly selective CDK9 inhibitor) so far has received both fast track and orphan drug designations from the FDA for the treatment of adult patients with relapsed/refractory (r/r) peripheral T-cell lymphomas (PTCL) and r/r acute myeloid leukemia (AML).

Key Points: 
  • GFH009 (highly selective CDK9 inhibitor) so far has received both fast track and orphan drug designations from the FDA for the treatment of adult patients with relapsed/refractory (r/r) peripheral T-cell lymphomas (PTCL) and r/r acute myeloid leukemia (AML).
  • Numerous subjects in GFH009 studies achieved complete or partial responses, and superior safety profile & efficacy of GFH009 was observed in previous studies.
  • GenFleet is conducting a multi-center, open-label, single-arm study of GFH009 for the treatment of r/r PTCL in close to 40 sites in China.
  • GFH925 was granted with NDA acceptance, priority review and two breakthrough therapy designations in China; GFH009 received FDA fast track and orphan drug designations for two indications.

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Retrieved on: 
Monday, January 8, 2024
Baylor University, Baylor College of Medicine, Neoplasm, Risk, Leukapheresis, IND, MRD, DLBCL, FDA, Drug discovery, Service provider, Disease, Trial of the century, PCR, Therapy, Marker, Natural history, ARTEMIS, Vasileiou, Mutagenesis, Pancreatic cancer, Press release, Chong, Growth, HSCT, CD19, Patient, Acute myeloid leukemia, Safety, AML, Bone marrow, Food and Drug Administration, Female, APOLLO, Pharmaceutical industry

HOUSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced a restructuring of its clinical programs and a strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline. In addition, the Company reported a clinical update on the Phase 2 ARTEMIS study investigating MT-401, a multiTAA-specific T cell product, for the treatment of patients with acute myeloid leukemia (AML).

Key Points: 
  • The TACTAL study enrolled patients with Hodgkin’s and non-Hodgkin’s lymphoma and demonstrated clinical safety and efficacy with durable clinical responses for 6 years (Vasileiou et al, J Clin Oncol, 2021).
  • Today, Marker is providing a clinical update on the Phase 2 ARTEMIS clinical study (clinicaltrials.gov identifier: NCT04511130), and the direction it will pursue.
  • “We are encouraged by the clinical observations in patients with MRD in our AML study,” said Juan Vera, M.D., President and CEO of Marker Therapeutics.
  • Marker has secured non-dilutive funding to support the clinical investigation of a ready for use MT-401 product in patients with AML.

Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene

Retrieved on: 
Monday, January 8, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, RARA, Aplastic anemia, Bone marrow, New Drug Application, Syros, Azacitidine, Venetoclax, Patient, Acute myeloid leukemia, AML, Pharmaceutical industry

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today highlighted anticipated 2024 milestones to deliver on the value of tamibarotene.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today highlighted anticipated 2024 milestones to deliver on the value of tamibarotene.
  • In addition, we closed an approximately $45.0 million equity financing, providing us additional capital to advance the development of tamibarotene.
  • By the middle of the fourth quarter of 2024, we expect to report pivotal data from the SELECT-MDS-1 Phase 3 clinical trial.
  • Syros is also evaluating tamibarotene in combination with venetoclax and azacitidine in newly diagnosed unfit AML patients with RARA overexpression.

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Sunday, January 7, 2024
NAMD, Conference, Gene family, Partnership, Neoplasm, Tumor microenvironment, IND, Hematopoietic stem cell transplantation, Radionuclide, CD47, Data, Myelodysplastic syndrome, Macrophage, Molecular Partners, HSC, Society, CHF, Novartis, ASH, COVID-19, DARPin, Toxicity, RDT, CD16, Stem cell, HSCT, Patient, Acute myeloid leukemia, Safety, Therapy, AML, DLL3, Health, SITC, Pharmaceutical industry

53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.
  • Data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.
  • In addition to these updates, Novartis has returned the rights to the ensovibep program, previously under investigation for the treatment of COVID-19, to Molecular Partners.

Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

Retrieved on: 
Friday, January 5, 2024
Workforce, Gene, SNTI, Partnership, Food, Hepatocellular carcinoma, IND, Doctor of Philosophy, Therapy, Investigational New Drug, Bone marrow, Acute myeloid leukemia, Patient, AML, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced plans to streamline its business operations, including reducing its workforce by approximately 37 percent, to enable increased focus on SENTI-202, a first-in-class Logic Gated investigational cell therapy for the treatment of acute myeloid leukemia (“AML”). The Investigational New Drug (“IND”) application for SENTI-202 was cleared by the U.S. Food and Drug Administration (“FDA”) in December 2023 and the Company anticipates dosing the first patient in the second quarter of 2024. Additionally, the Company will continue to support the clinical development activities of SENTI-301A for the treatment of advanced glypican 3 (“GPC3”)-expressing hepatocellular carcinoma (“HCC”) in China through its partnership with Celest Therapeutics. The Company expects that these resource allocation efforts, combined with other expected receivables, will extend its cash runway into the first quarter of 2025.

Key Points: 
  • Additionally, the Company will continue to support the clinical development activities of SENTI-301A for the treatment of advanced glypican 3 (“GPC3”)-expressing hepatocellular carcinoma (“HCC”) in China through its partnership with Celest Therapeutics.
  • The Company expects that these resource allocation efforts, combined with other expected receivables, will extend its cash runway into the first quarter of 2025.
  • Despite this progress, we are taking the difficult but necessary steps to enhance our focus on demonstrating clinical proof-of-concept for our Gene Circuit technology and potentially bringing SENTI-202 and SENTI-301A to patients,” said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio.
  • “With these resource allocation efforts, our team will remain laser-focused on the clinical progress of SENTI-202 and supporting our partnership with Celest Therapeutics for SENTI-301A in China.

Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

Retrieved on: 
Friday, January 5, 2024
Omalizumab, Subcutaneous, CD117, Risk, IND, EMA, FA, Chairperson, Cold urticaria, Therapy, MDS, Chronic, Fanconi anemia, ASH, Annual general meeting, European Medicines Agency, Syndrome, CSU, SVP, Patient, Acute myeloid leukemia, Safety, AML, CTA, Pharmaceutical industry

REDWOOD CITY, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced its recent accomplishments, including the authorization by the European Medicines Agency (EMA) of the Company’s Clinical Trial Applications (CTA) for its Phase 1b/2a trials of briquilimab in CIndU and CSU, and outlined its corporate priorities and anticipated milestones for 2024. Called SPOTLIGHT – “Study (Phase 1b/2a) Of subcuTaneous brIquilimab in patients diaGnosed with cHronic inducible urTicaria” – the CIndU study will evaluate single doses of subcutaneous briquilimab in adult patients with cold urticaria or symptomatic dermographism.

Key Points: 
  • “2023 was a strategically important year for Jasper,” said Ronald Martell, President and Chief Executive Officer of Jasper.
  • “We secured IND clearance and CTA authorization for the Phase 1b/2a BEACON study of briquilimab in CSU and successfully dosed the first patient.
  • Our achievements in 2023 set the stage for a transformational year ahead with multiple key clinical milestones on the horizon across multiple indications.
  • Strengthened the organization with key leadership appointments including Thomas Wiggans as Chairperson of the Board of Directors, Scott Brun, M.D.